Navigation Links
SuperGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 10, 2008
Date:11/3/2008

DUBLIN, Calif., Nov 3 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S. Manuso, Ph.D., President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008, at the New York Palace Hotel.

SuperGen's presentation at the Rodman & Renshaw 10th Annual Healthcare Conference is scheduled to begin at 11:35 a.m. EDT (8:35 a.m. PDT). A live webcast of the presentation will be available on the investor relations section of the Company's Web site at http://www.supergen.com. The webcast will be archived for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Contacts:

SuperGen, Inc.

Timothy L. Enns

SVP, Corporate Communications

& Business Development

Tel: (925) 560-0100

Email: tenns@supergen.com

Mary M. Vegh

Manager, Investor Relations

Tel: (925) 560-2845

E-mail: mary.vegh@supergen.com

Dorland Global Public Relations

Michael Beckerich (Media)

Tel: (212) 677-7632

mbeckerich@dorland.com


'/>"/>
SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
2. SuperGen to Announce 2007 Third Quarter Financial Results October 29, 2007
3. SuperGen Reports 2007 Third Quarter Financial Results
4. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
5. SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008
6. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
7. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
8. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
9. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
10. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
11. AtriCure to Present at Roth Capital Partners 2007 New York Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , ... January 16, 2017 , ... San Francisco dentist, ... Element, the latest in 3-D scanning device which is capable of taking digital impressions ... advances in dentistry, such as CAD CAM restorations , in terms of speed, ...
(Date:1/15/2017)... NY (PRWEB) , ... January 15, 2017 , ... In ... accounts in the United States for the asthma & allergy friendly mark. This certification ... to independently test and identify consumer products to be more suitable for the 60+ ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation ... achieved accreditation for its specialty care services. Albertsons Companies is the largest ... care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication ...
(Date:1/15/2017)... ... January 14, 2017 , ... Wondering where to go this Valentine's Day? Well, ... door for a romantic, lobster feast in the comfort of your own home. Lobster ... The dinners will be featured until February 15th, 2017. , Romantic Dinner one is ...
(Date:1/14/2017)... Minneapolis, MN (PRWEB) , ... January 14, 2017 ... ... to present the distinctions among their expanding line of activated charcoal products. With ... emphasizes the importance of categorizing their products according to how they cater to ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... PORTLAND, Oregon and PUNE, India , January 16, ... Market Research, titled, "Antioxidants Market by Type - Global Opportunity Analysis and Industry ... and is expected to reach $4,531 million by 2022, registering a CAGR of ... accounted for more than one-third share of the global volume in 2015. ... ...
(Date:1/16/2017)... 2017 Bill is an internationally experienced medical ... and leadership positions with global medical device companies, including Smith & ... of launching new products and building successful businesses in the sector ... Africa and North America . ... Educated at the University ...
(Date:1/16/2017)... Calif. , Jan. 16, 2017  Rigel Pharmaceuticals ... January 3, 2017 and January 16, 2017 the Compensation ... of inducement stock options to purchase an aggregate of ... These awards were granted pursuant to the Rigel Pharmaceuticals, ... to the new employees entering into employment with Rigel, ...
Breaking Medicine Technology: